These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
412 related articles for article (PubMed ID: 32426454)
1. Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer's disease. Mattsson-Carlgren N; Andersson E; Janelidze S; Ossenkoppele R; Insel P; Strandberg O; Zetterberg H; Rosen HJ; Rabinovici G; Chai X; Blennow K; Dage JL; Stomrud E; Smith R; Palmqvist S; Hansson O Sci Adv; 2020 Apr; 6(16):eaaz2387. PubMed ID: 32426454 [TBL] [Abstract][Full Text] [Related]
2. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Thijssen EH; La Joie R; Strom A; Fonseca C; Iaccarino L; Wolf A; Spina S; Allen IE; Cobigo Y; Heuer H; VandeVrede L; Proctor NK; Lago AL; Baker S; Sivasankaran R; Kieloch A; Kinhikar A; Yu L; Valentin MA; Jeromin A; Zetterberg H; Hansson O; Mattsson-Carlgren N; Graham D; Blennow K; Kramer JH; Grinberg LT; Seeley WW; Rosen H; Boeve BF; Miller BL; Teunissen CE; Rabinovici GD; Rojas JC; Dage JL; Boxer AL; Lancet Neurol; 2021 Sep; 20(9):739-752. PubMed ID: 34418401 [TBL] [Abstract][Full Text] [Related]
3. Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease. Janelidze S; Berron D; Smith R; Strandberg O; Proctor NK; Dage JL; Stomrud E; Palmqvist S; Mattsson-Carlgren N; Hansson O JAMA Neurol; 2021 Feb; 78(2):149-156. PubMed ID: 33165506 [TBL] [Abstract][Full Text] [Related]
4. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model. Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W; J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262 [TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease. Ashton NJ; Benedet AL; Pascoal TA; Karikari TK; Lantero-Rodriguez J; Brum WS; Mathotaarachchi S; Therriault J; Savard M; Chamoun M; Stoops E; Francois C; Vanmechelen E; Gauthier S; Zimmer ER; Zetterberg H; Blennow K; Rosa-Neto P EBioMedicine; 2022 Feb; 76():103836. PubMed ID: 35158308 [TBL] [Abstract][Full Text] [Related]
6. Correlation between Cerebrospinal Fluid Core Alzheimer's Disease Biomarkers and β-Amyloid PET in Chinese Dementia Population. Xie Q; Ni M; Gao F; Dai LB; Lv XY; Zhang YF; Shi Q; Zhu XX; Xie JK; Shen Y; Wang SC ACS Chem Neurosci; 2022 May; 13(10):1558-1565. PubMed ID: 35476397 [TBL] [Abstract][Full Text] [Related]
10. Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease. Pereira JB; Janelidze S; Smith R; Mattsson-Carlgren N; Palmqvist S; Teunissen CE; Zetterberg H; Stomrud E; Ashton NJ; Blennow K; Hansson O Brain; 2021 Dec; 144(11):3505-3516. PubMed ID: 34259835 [TBL] [Abstract][Full Text] [Related]
11. Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer's Disease. Lantero-Rodriguez J; Salvadó G; Snellman A; Montoliu-Gaya L; Brum WS; Benedet AL; Mattsson-Carlgren N; Tideman P; Janelidze S; Palmqvist S; Stomrud E; Ashton NJ; Zetterberg H; Blennow K; Hansson O Mol Neurodegener; 2024 Feb; 19(1):19. PubMed ID: 38365825 [TBL] [Abstract][Full Text] [Related]
12. Amyloid PETs are commonly negative in suspected Alzheimer's disease with an increase in CSF phosphorylated-tau protein concentration but an Aβ42 concentration in the very high range: a prospective study. Manca C; Rivasseau Jonveaux T; Roch V; Marie PY; Karcher G; Lamiral Z; Malaplate C; Verger A J Neurol; 2019 Jul; 266(7):1685-1692. PubMed ID: 30963253 [TBL] [Abstract][Full Text] [Related]
13. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease. Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318 [TBL] [Abstract][Full Text] [Related]